➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Express Scripts
Medtronic

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,650,441

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,650,441
Title:Anti-CD47 antibodies and methods of use
Abstract: Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.
Inventor(s): Grosveld; Frank (Rotterdam, NL), Palombella; Vito (Needham, MA), Holland; Pamela M. (Belmont, MA), Paterson; Alison (Dedham, MA), Hill; Jonathan (Salem, MA)
Assignee: Erasmus University Medical Center (Rotterdam, NL) Surface Oncology, Inc. (Cambridge, MA)
Application Number:15/271,861
Patent Claims:1. A method of treating cancer in a subject in need thereof, wherein the cancer comprises cells that express CD47, the method comprising administering to the subject an effective amount of an isolated anti-CD47 antibody molecule comprising a heavy chain complementarity determining region 1 (HC CDR1) of the amino acid sequence set forth in SEQ ID NO: 7, a heavy chain complementarity determining region 2 (HC CDR2) of the amino acid sequence set forth in SEQ ID NO: 8, a heavy chain complementarity determining region 3 (HC CDR3) of the amino acid sequence set forth in SEQ ID NO: 9, a light chain complementarity determining region 1 (LC CDR1) of the amino acid sequence set forth in SEQ ID NO: 10, a light chain complementarity determining region 2 (LC CDR2) of the amino acid sequence set forth in SEQ ID NO: 11, and a light chain complementarity determining region 3 (LC CDR3) of the amino acid sequence set forth in SEQ ID NO: 12.

2. The method of claim 1, wherein the anti-CD47 antibody molecule is administered in combination with a chemotherapeutic agent or therapeutic antibody molecule.

3. The method of claim 1, wherein the anti-CD47 antibody molecule is administered in combination with an opsonizing antibody molecule.

4. The method of claim 3, wherein the opsonizing antibody molecule is an anti-CD19 antibody molecule, an anti-CD20 antibody molecule, or an anti-CD38 antibody molecule.

5. The method of claim 4, wherein the opsonizing antibody molecule is an anti-CD20 antibody molecule.

6. The method of claim 4, wherein the antibody molecule is rituximab.

7. The method of claim 1, wherein the cancer i a hematological cancer.

8. The method of claim 7, wherein the hematological cancer is selected from the group consisting of: acute lymphoblastic leukemia (ALL), T-ALL, B-ALL, acute myelogenous leukemia (AML), Non-Hodgkin lymphoma, B-lymphoblastic leukemia/lymphoma; B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), Burkitt's lymphoma, follicular lymphoma, SLL, marginal zone lymphoma, CNS lymphoma, Richter's Syndrome, multiple myeloma, myelofibrosis, polycythemia vera, cutaneous T-cell lymphoma, MGUS, myelodysplastic syndrome (MDS), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and anaplastic large cell lymphoma.

9. The method of claim 8, wherein the hematological cancer is acute myelogenous leukemia (AML) or Burkitt's lymphoma.

10. The method of claim 1, wherein the cancer is a solid tumor.

11. The method of claim 10, wherein the cancer is a cancer of a tissue selected from the group consisting of: lung, pancreas, breast, liver, ovary, testicle, kidney, bladder, spine, brain, cervix, endometrium, colon/rectum, anus, esophagus, gallbladder, gastrointestinal tract, skin, prostate, pituitary, stomach, uterus, vagina, and thyroid.

12. The method of claim 1, wherein the anti-CD47 antibody molecule comprises a heavy chain variable region (VH) of the amino acid sequence set forth in SEQ TD NO: 4 and a light chain variable region (VL) of the amino acid sequence set forth in SEQ ID NO: 6.

13. The method of claim 1, wherein the anti-CD47 antibody molecule further comprises a wild type or mutant IgG1 heavy chain constant region.

14. The method of claim 1, wherein the anti-CD47 antibody molecule further comprises a wild type or mutant IgG4 heavy chain constant region.

15. The method of claim 14, wherein the IgG4 heavy chain constant region comprises one or both of the substitutions S228P and L235E.

16. The method of claim 1, wherein the anti-CD47 antibody molecule comprises a heavy chain of the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 23, SEQ ID NO: 24, or SEQ ID NO: 25, and a light chain of the amino acid sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 26.

17. The method of claim 1, wherein the anti-CD47 antibody molecule is administered in combination with a pharmaceutically acceptable carrier or diluent.

18. The method of claim 1, wherein the anti-CD47 antibody molecule is administered subcutaneously.

19. The method of claim 1, wherein the anti-CD47 antibody molecule is administered intravenously.

20. The method of claim 1, wherein the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, breast cancer, stomach cancer, colon cancer, prostate cancer, and uterine cancer.

Details for Patent 9,650,441

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Erasmus University Medical Center (Rotterdam, NL) Surface Oncology, Inc. (Cambridge, MA) 2035-09-21 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Erasmus University Medical Center (Rotterdam, NL) Surface Oncology, Inc. (Cambridge, MA) 2035-09-21 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Erasmus University Medical Center (Rotterdam, NL) Surface Oncology, Inc. (Cambridge, MA) 2035-09-21 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Erasmus University Medical Center (Rotterdam, NL) Surface Oncology, Inc. (Cambridge, MA) 2035-09-21 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Dow
Johnson and Johnson
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.